Atopic Dermatitis Clinical Trials in Jacksonville, Florida

4 studies are recruiting for atopic dermatitis in Jacksonville, Florida right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. A Long-term Safety and Efficacy Study Evaluating APG777 in Atopic Dermatitis

   This is a multicenter, double-blind, Long-Term Extension (LTE) study to evaluate the long-term safety and efficacy of APG777 in patients with moderate-to-severe AD who have completed treatment in an APG777 Parent Study (NCT06395948). The LTE study will consist of 3 periods: 1) Screening Visit will …

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Investigational Site, Jacksonville, Florida

   Locations

   71 in total

   Run by

   Apogee Therapeutics, Inc.

   See if you can join NCT07003425 on ClinicalTrials.gov

2. A Long-term Study of the Medicine Called Abrocitinib in Children Aged 2 Years and Older With Moderate to Severe Eczema

   This 24-month study will assess the long-term safety and efficacy of liquid abrocitinib oral suspension with or without topical medications in children 2 years of age or older with moderate-to-severe atopic dermatitis. The study will enroll two groups: participants who have completed other abrociti…

   Stage

   Phase 3

   Ages

   2 to 11

   Site

   Solutions Through Advanced Research, Jacksonville, Florida

   Locations

   41 in total

   Run by

   Pfizer

   See if you can join NCT06807281 on ClinicalTrials.gov

3. A Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Children and Infants With Moderate-to-severe Atopic Dermatitis

   The purpose of this trial is to test whether treatment with tralokinumab (administered subcutaneous injections [SC]) in combination with topical corticosteroids (TCS) is safe and effective to treat moderate-to-severe atopic dermatitis (AD) in children and infants. This will be judged by a range of …

   Stage

   Phase 3

   Ages

   0 to 11

   Site

   Leo Pharma Investigational site, Jacksonville, Florida

   Locations

   72 in total

   Run by

   LEO Pharma

   See if you can join NCT06311682 on ClinicalTrials.gov

4. A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab

   Atopic dermatitis (AD) is a skin condition that may cause a rash and itching due to inflammation of the skin. Therapies spread over the skin may not be enough to control the AD in trial participants who require systemic anti-inflammatory treatment. This study aims to provide data on the efficacy an…

   Stage

   Phase 3

   Ages

   18 to 63

   Site

   Solutions Through Advanced Research /ID# 263392, Jacksonville, Florida

   Locations

   128 in total

   Run by

   AbbVie

   See if you can join NCT06389136 on ClinicalTrials.gov